Coya Therapeutics Inc. (COYA)
Coya Therapeutics Statistics
Share Statistics
Coya Therapeutics has 16.72M shares outstanding. The number of shares has increased by 9.88% in one year.
| Shares Outstanding | 16.72M |
| Shares Change (YoY) | 9.88% |
| Shares Change (QoQ) | 0.11% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.55M |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 294.08K, so 1.76% of the outstanding shares have been sold short.
| Short Interest | 294.08K |
| Short % of Shares Out | 1.76% |
| Short % of Float | 1.89% |
| Short Ratio (days to cover) | 5.09 |
Valuation Ratios
The PE ratio is -5.87 and the forward PE ratio is -4.35. Coya Therapeutics's PEG ratio is -0.24.
| PE Ratio | -5.87 |
| Forward PE | -4.35 |
| PS Ratio | 0.02 |
| Forward PS | 3.6 |
| PB Ratio | 0 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | -0.24 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Coya Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.59, with a Debt / Equity ratio of 0.
| Current Ratio | 11.59 |
| Quick Ratio | 11.59 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $444.26M |
| Profits Per Employee | $-1.86M |
| Employee Count | 8 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 720.29M |
| Effective Tax Rate | -5.09% |
Stock Price Statistics
The stock price has increased by -22% in the last 52 weeks. The beta is 0.5, so Coya Therapeutics's price volatility has been higher than the market average.
| Beta | 0.5 |
| 52-Week Price Change | -22% |
| 50-Day Moving Average | 6.28 |
| 200-Day Moving Average | 6.43 |
| Relative Strength Index (RSI) | 58.44 |
| Average Volume (20 Days) | 99.82K |
Income Statement
In the last 12 months, Coya Therapeutics had revenue of 3.55B and earned -14.88M in profits. Earnings per share was -0.98.
| Revenue | 3.55B |
| Gross Profit | 3.55B |
| Operating Income | -17.25B |
| Net Income | -14.88M |
| EBITDA | -17.22M |
| EBIT | -17.25M |
| Earnings Per Share (EPS) | -0.98 |
Balance Sheet
The company has 38.34M in cash and 0 in debt, giving a net cash position of 38.34M.
| Cash & Cash Equivalents | 38.34M |
| Total Debt | 0 |
| Net Cash | 38.34M |
| Retained Earnings | -40.74B |
| Total Assets | 44.35M |
| Working Capital | 40.48M |
Cash Flow
In the last 12 months, operating cash flow was -10.29B and capital expenditures 0, giving a free cash flow of -10.29B.
| Operating Cash Flow | -10.29B |
| Capital Expenditures | 0 |
| Free Cash Flow | -10.29B |
| FCF Per Share | -675.17 |
Margins
Gross margin is 100%, with operating and profit margins of -485.35% and -0.42%.
| Gross Margin | 100% |
| Operating Margin | -485.35% |
| Pretax Margin | -398.43% |
| Profit Margin | -0.42% |
| EBITDA Margin | -0.48% |
| EBIT Margin | -485.35% |
| FCF Margin | -289.49% |
Dividends & Yields
COYA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for COYA is $18, which is 174.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 174.4% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 90.68 |
| Piotroski F-Score | 4 |